HK1216897A1 - 識別 的磷酸化特異抗體 - Google Patents

識別 的磷酸化特異抗體

Info

Publication number
HK1216897A1
HK1216897A1 HK16104710.3A HK16104710A HK1216897A1 HK 1216897 A1 HK1216897 A1 HK 1216897A1 HK 16104710 A HK16104710 A HK 16104710A HK 1216897 A1 HK1216897 A1 HK 1216897A1
Authority
HK
Hong Kong
Prior art keywords
tau
phospho
antibodies recognising
recognising
antibodies
Prior art date
Application number
HK16104710.3A
Other languages
English (en)
Inventor
Andrea Pfeifer
Andreas Muhs
Leuven Fred Van
Maria Pihlgren
Oskar Adolfsson
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44947048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1216897(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Publication of HK1216897A1 publication Critical patent/HK1216897A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
HK16104710.3A 2010-10-07 2016-04-25 識別 的磷酸化特異抗體 HK1216897A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10186810 2010-10-07
EP11174248 2011-07-15

Publications (1)

Publication Number Publication Date
HK1216897A1 true HK1216897A1 (zh) 2016-12-09

Family

ID=44947048

Family Applications (2)

Application Number Title Priority Date Filing Date
HK14100845.1A HK1187928A1 (zh) 2010-10-07 2014-01-27 識別磷酸化- 的抗體
HK16104710.3A HK1216897A1 (zh) 2010-10-07 2016-04-25 識別 的磷酸化特異抗體

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK14100845.1A HK1187928A1 (zh) 2010-10-07 2014-01-27 識別磷酸化- 的抗體

Country Status (28)

Country Link
US (2) US9304138B2 (zh)
EP (2) EP2625198B1 (zh)
JP (2) JP6371526B2 (zh)
KR (1) KR101988672B1 (zh)
CN (1) CN103502272B (zh)
AR (1) AR085198A1 (zh)
AU (1) AU2011311516B2 (zh)
BR (1) BR112013008333B1 (zh)
CA (1) CA2812865C (zh)
CL (1) CL2013000951A1 (zh)
CO (1) CO6710903A2 (zh)
CR (1) CR20130160A (zh)
DK (1) DK2625198T3 (zh)
EC (1) ECSP13012609A (zh)
ES (1) ES2548686T3 (zh)
HK (2) HK1187928A1 (zh)
HU (1) HUE027649T2 (zh)
IL (1) IL225568A (zh)
MX (1) MX338421B (zh)
MY (1) MY164376A (zh)
PE (1) PE20140218A1 (zh)
PL (1) PL2625198T3 (zh)
RU (1) RU2603078C2 (zh)
SG (1) SG189136A1 (zh)
SI (1) SI2625198T1 (zh)
TW (1) TW201216985A (zh)
WO (1) WO2012045882A2 (zh)
ZA (1) ZA201302432B (zh)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10266585B2 (en) * 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
WO2012045882A2 (en) * 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition
WO2012049570A1 (en) 2010-10-11 2012-04-19 Panima Pharmaceuticals Ag Human anti-tau antibodies
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
EP2764022B9 (en) 2011-10-07 2017-02-22 AC Immune S.A. Phosphospecific antibodies recognising tau
EP3578567A1 (en) 2011-12-20 2019-12-11 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
KR102132041B1 (ko) * 2012-04-05 2020-07-09 에이씨 이뮨 에스.에이. 인간화된 타우 항체
CA2877397A1 (en) 2012-07-03 2014-01-09 Washington University Antibodies to tau
WO2014016737A1 (en) * 2012-07-24 2014-01-30 Pfizer Inc. Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
MY176838A (en) 2012-08-16 2020-08-24 Ipierian Inc Methods of treating a tauopathy
US12024568B2 (en) 2012-09-13 2024-07-02 Cornell University Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
LT2935326T (lt) * 2012-12-21 2020-12-10 Biogen Ma Inc. Žmogaus antikūnai prieš tau baltymą
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
EP2970452A2 (en) * 2013-03-15 2016-01-20 AC Immune S.A. Anti-tau antibodies and methods of use
SG10201708143QA (en) 2013-06-06 2017-11-29 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
GB201312226D0 (en) * 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US20160289309A1 (en) * 2013-11-27 2016-10-06 Ipierian, Inc. Methods of treating a tauopathy
ES2778498T3 (es) 2013-12-20 2020-08-10 Hoffmann La Roche Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
US10400018B2 (en) * 2014-02-14 2019-09-03 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
KR102502356B1 (ko) 2014-09-30 2023-02-21 워싱턴 유니버시티 타우 (tau) 활동 계측
SG11201703237VA (en) * 2014-11-19 2017-06-29 Axon Neuroscience Se Humanized tau antibodies in alzheimer's disease
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對ｔａｕ之抗體及其用途
WO2016196726A1 (en) 2015-06-05 2016-12-08 Genentech, Inc. Anti-tau antibodies and methods of use
JP6619460B2 (ja) 2015-06-24 2019-12-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ヒト化抗タウ（ｐＳ４２２）抗体及び使用法
SG10202010735PA (en) 2015-07-06 2020-11-27 UCB Biopharma SRL Tau-binding antibodies
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
EP3334761B1 (en) * 2015-08-13 2023-07-19 New York University Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
DK3484916T3 (da) * 2016-07-12 2021-04-06 H Lundbeck As Antistoffer specifikke for hyperphosphoryleret tau og fremgangsmåder til anvendelse deraf
EP3496750A2 (en) 2016-08-09 2019-06-19 Eli Lilly and Company Combination therapy
WO2018106776A2 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
WO2018106781A1 (en) * 2016-12-07 2018-06-14 Genentech, Inc Anti-tau antibodies and methods of use
CN110267985B (zh) * 2017-01-04 2023-05-23 H.隆德贝克有限公司 用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体
CN110520440A (zh) 2017-02-17 2019-11-29 戴纳立制药公司 抗τ抗体及其使用方法
JP2018139530A (ja) * 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
EA039569B1 (ru) * 2017-03-14 2022-02-11 Х. Лундбекк А/С Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
WO2018217630A1 (en) * 2017-05-21 2018-11-29 University Of Tennessee Research Foundation Methods and compositions for targeting tissue lesions
AU2018352308A1 (en) 2017-10-16 2020-03-19 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
WO2019107370A1 (ja) * 2017-11-28 2019-06-06 国立大学法人三重大学 検出方法
JP2021530552A (ja) 2018-07-31 2021-11-11 イーライ リリー アンド カンパニー 併用療法
US12116415B2 (en) * 2018-10-09 2024-10-15 Single Cell Technology, Inc. Anti-BCMA antibodies
US20210347869A1 (en) * 2018-10-17 2021-11-11 The University Of Queensland Methods and compositions for treating tauopathies
WO2020097155A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
CN113874496A (zh) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) 人源化细胞系
CA3135170A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
MX2021012488A (es) * 2019-04-12 2021-11-12 Phanes Therapeutics Inc Receptores de antigeno quimerico del receptor 1 anti-folato humanizado y usos de los mismos.
CN110028583B (zh) * 2019-05-07 2020-09-11 温州医科大学 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用
EP4022046A2 (en) 2019-08-27 2022-07-06 Wisconsin Alumni Research Foundation (WARF) Recombinant influenza viruses with stabilized ha for replication in eggs
CN112752251B (zh) * 2019-10-29 2022-05-06 中国移动通信有限公司研究院 一种ue标识符的分配方法、装置和计算机可读存储介质
AU2021217290A1 (en) * 2020-02-05 2022-07-21 Sumitomo Pharma Co., Ltd. Determination agent and determination method for tauopathy and dementia-related diseases
EP4171633A1 (en) 2020-06-25 2023-05-03 Merck Sharp & Dohme LLC High affinity antibodies targeting tau phosphorylated at serine 413
EP4014997A1 (en) 2020-12-16 2022-06-22 Consejo Superior de Investigaciones Científicas (CSIC) Stard1 inhibitors for the treatment of lysosomal disorders
AU2021403010A1 (en) * 2020-12-16 2023-07-13 Voyager Therapeutics, Inc. Tau binding compounds
WO2022197890A1 (en) * 2021-03-18 2022-09-22 Seagen Inc. Anti-alpp/alppl2 antibodies and antibody-drug conjugates
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
EP0618968B1 (en) 1991-12-06 1999-10-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
CA2141216A1 (en) 1992-07-27 1994-02-03 Michael J. Micklus Targeting of liposomes to the blood-brain barrier
US7129337B1 (en) 1994-10-21 2006-10-31 Innogenetics N.V. Sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
US5756662A (en) 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
US20020086009A1 (en) * 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
AU5508798A (en) * 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
AU2001273361A1 (en) * 2000-07-11 2002-01-21 Molecular Geriatrics Corporation Reagents and methods for identification of binding agents
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US20020065259A1 (en) 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
KR101186210B1 (ko) 2002-12-03 2012-10-08 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 혈뇌장벽을 통과하는 물질 수송용 인공 저밀도 지단백질 운반체
AU2003292936A1 (en) 2002-12-24 2004-07-22 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
EP1663239A4 (en) 2003-09-10 2008-07-23 Cedars Sinai Medical Center KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER
US7238788B2 (en) 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
BRPI0516962A (pt) 2004-10-25 2008-09-30 Univ Northwestern anticorpo isolado, ou fragmento do mesmo, composição farmacêutica, métodos para prevenir a ligação de ligantes difundìveis derivados de abeta a um neurÈnio, para inibir a constituição de ligantes difundìveis, para bloquear a fosforilação de proteìna, para tratar profilaticamente ou terapeuticamente uma doença, para identificar um agente terapêutico, para detectar ligantes difundìveis, e para diagnosticar uma doença, e, kit para detectar ligantes difundìveis
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20080220449A1 (en) 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
US9555032B2 (en) 2007-06-13 2017-01-31 Research Development Foundation Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling
SG185316A1 (en) 2007-10-19 2012-11-29 Immunas Pharma Inc ANTIBODY CAPABLE OF SPECIFICALLY BINDING TO Aβ OLIGOMER, AND USE THEREOF
DK2408807T3 (da) * 2009-03-18 2021-08-09 Ac Immune Sa Fremgangsmåde til terapeutisk anvendelse
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
EP3329932A1 (en) * 2009-06-10 2018-06-06 New York University Immunological targeting of pathological tau proteins
MX2012001194A (es) * 2009-07-30 2012-03-07 Pfizer Vaccines Llc Peptidos tau antigenicos y usos de los mismos.
WO2012045882A2 (en) * 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition

Also Published As

Publication number Publication date
MX338421B (es) 2016-04-15
CN103502272A (zh) 2014-01-08
MX2013003800A (es) 2013-06-28
ECSP13012609A (es) 2013-07-31
BR112013008333B1 (pt) 2022-10-11
IL225568A (en) 2017-06-29
MY164376A (en) 2017-12-15
BR112013008333A2 (pt) 2021-09-21
RU2013120544A (ru) 2014-11-20
JP2017113004A (ja) 2017-06-29
US9304138B2 (en) 2016-04-05
EP2625198A2 (en) 2013-08-14
CR20130160A (es) 2013-09-03
EP2987807A3 (en) 2016-06-01
SI2625198T1 (sl) 2015-11-30
KR20130115279A (ko) 2013-10-21
CA2812865A1 (en) 2012-04-12
US20120276009A1 (en) 2012-11-01
AU2011311516B2 (en) 2015-06-11
JP2014502141A (ja) 2014-01-30
WO2012045882A2 (en) 2012-04-12
CN103502272B (zh) 2016-06-15
EP2625198B1 (en) 2015-07-22
US20160304590A1 (en) 2016-10-20
PE20140218A1 (es) 2014-03-01
CL2013000951A1 (es) 2014-01-03
EP2987807A2 (en) 2016-02-24
CA2812865C (en) 2021-01-26
PL2625198T3 (pl) 2015-12-31
AU2011311516A1 (en) 2013-04-18
ES2548686T3 (es) 2015-10-20
CO6710903A2 (es) 2013-07-15
KR101988672B1 (ko) 2019-06-12
RU2603078C2 (ru) 2016-11-20
IL225568A0 (en) 2013-06-27
SG189136A1 (en) 2013-05-31
DK2625198T3 (en) 2015-09-28
AR085198A1 (es) 2013-09-18
HK1187928A1 (zh) 2014-04-17
ZA201302432B (en) 2016-07-27
HUE027649T2 (en) 2016-10-28
US10100104B2 (en) 2018-10-16
JP6371526B2 (ja) 2018-08-08
TW201216985A (en) 2012-05-01
WO2012045882A3 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
HK1216897A1 (zh) 識別 的磷酸化特異抗體
HRP20180952T1 (hr) Anti-dll3 antitijelo
HK1200469A1 (zh) 識別 的磷酸化特異抗體
ZA201209004B (en) Anti-fgfr2 antibodies
ZA201208290B (en) Anti-erbb3 antibodies
GB201000467D0 (en) Antibodies
IL221371A0 (en) Anti-lrp6 antibodies
HUE040213T2 (hu) Anti-TIM antitest
PL2616489T3 (pl) Przeciwciało anty-huTNFR1
IL225667A0 (en) A new antigen
HK1194388A1 (zh) 抗缺刻蛋白 抗體
PL2603528T3 (pl) Przeciwciała Fab-glikozylowane
GB201020738D0 (en) Antibodies
ZA201206055B (en) Antibodies against cxcr4
GB201012651D0 (en) Peptides
ZA201302459B (en) Antibodies
EP2601217A4 (en) ANTIBODIES DIRECTED AGAINST IL-17
AU334106S (en) Cup
EP2627674A4 (en) EGFR BASED PEPTIDES
GB201112352D0 (en) Sorter
GB201115171D0 (en) An improved container
TWM385994U (en) Tea-filtering cup
GB201007957D0 (en) Antibody
GB201020751D0 (en) Antibodies
GB201005062D0 (en) Antibodies